VitaSpring Biomedical Co. Ltd.
VSBC
$0.01
-$0.24-95.56%
OTC PK
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -1.49M | -1.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -1.49M | -1.49M |
| Cost of Revenue | -- | -- | -- | 2.41M | 2.41M |
| Gross Profit | -- | -- | -- | -3.90M | -3.90M |
| SG&A Expenses | 895.90K | 1.03M | 1.12M | 1.16M | 1.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 895.90K | 1.03M | 1.12M | 3.57M | 3.51M |
| Operating Income | -895.90K | -1.03M | -1.12M | -5.06M | -5.00M |
| Income Before Tax | -895.90K | -1.03M | -1.12M | -5.06M | -5.01M |
| Income Tax Expenses | -- | -- | -- | -4.50K | -50.10K |
| Earnings from Continuing Operations | -0.90 | -1.03 | -1.12 | -5.05 | -4.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -895.90K | -1.03M | -1.12M | -5.05M | -4.96M |
| EBIT | -895.90K | -1.03M | -1.12M | -5.06M | -5.00M |
| EBITDA | -883.30K | -1.02M | -1.10M | -5.04M | -4.99M |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.02 | -0.02 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 828.12M | 828.12M | 828.12M | 827.62M | 827.11M |
| Average Diluted Shares Outstanding | 828.12M | 828.12M | 828.12M | 827.62M | 827.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |